ArTara Therapeutics has completed an end-of-phase 2 meeting with the FDA to discuss a phase 3 study of intravenous choline chloride substrate replacement for patients with intestinal failure-associated liver disease, according to a press release.
Results from the phase 2 randomized control study met its two objectives for intestinal failure-associated liver disease (IFALD): steatosis reversal and improvement in cholestasis.
“When left untreated, these pathologies combine in IFALD patients to cause steady progression to end-stage liver disease,” Jesse Shefferman, CEO of ArTara, said
You may also like
Marcia Cross of 'Desperate Housewives' Opens Up on Anal Cancer
- April 21, 2019
(MedPage Today) — ActressRead more
GAP Regimen Tops Historical Data for Advanced Biliary Tract Ca
- April 20, 2019
(MedPage Today) — ResultsRead more